ZER has been shown to reduce the neoplasticity and motility of TNBC cells by inhibiting the TGF-β1 signaling pathway and can increase the sensitivity of BC cells to paclitaxel [243–246]. The gene discussed is TGFB1; the disease is breast cancer.